FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166568517> ?p ?o ?g. }

• W2166568517 endingPage "9" @default.
• W2166568517 startingPage "451" @default.
• W2166568517 abstract "Currently, there is no therapy for men with androgen-refractory prostate cancer that substantially extends survival. This report characterizes by in vitro and in vivo techniques a new chemotherapeutic that is composed of desacetyl-vinblastine covalently linked to a peptide that contains a peptide bond that can be hydrolyzed by prostate-specific antigen (PSA). This compound (referred to as vinblastine-conjugate) is minimally toxic to cells in culture which do not express PSA. In the presence of PSA, the peptide moiety is hydrolyzed, generating several highly toxic metabolites that contain vinblastine. Animals bearing PSA-positive human prostate tumors that were treated with the vinblastine-conjugate experienced a >99% reduction in PSA serum level. In contrast, animals bearing PSA-positive human prostate tumors treated with the cytotoxic metabolites derived from the PSA hydrolysis of the vinblastine-conjugate showed a nonsignificant change in both PSA and tumor weight values. The cell killing activity of the vinblastine-conjugate is PSA dependent because animals bearing non-PSA-producing human tumor xenografts had a nonsignificant increase in tumor weight after vinblastine-conjugate treatment. Exploratory efficacy/toxicity studies in LNCaP tumor-bearing nude mice were conducted with animals treated for 5 consecutive days with various doses of either the vinblastine-conjugate or a PSA-generated toxic metabolite (desacetyl-vinblastine). The desacetyl-vinblastine treatment resulted in 10-70% mortality with a very slight effect on tumor growth. In contrast, vinblastine-conjugate treatments resulted in no mortality, good to excellent antitumor efficacy, very slight to slight peripheral neuropathy and myelopathy, and slight to severe testicular degeneration. Similar treatment of beagle dogs with the vinblastine-conjugate showed even less toxicity. These data support the use of the PSA-hydrolyzable vinblastine-conjugate as an experimental therapy for prostate cancer in man." @default.
• W2166568517 created "2016-06-24" @default.
• W2166568517 creator A5005761697 @default.
• W2166568517 creator A5009676744 @default.
• W2166568517 creator A5013184259 @default.
• W2166568517 creator A5017385481 @default.
• W2166568517 creator A5017507332 @default.
• W2166568517 creator A5019353427 @default.
• W2166568517 creator A5020195400 @default.
• W2166568517 creator A5025950734 @default.
• W2166568517 creator A5030751523 @default.
• W2166568517 creator A5036690318 @default.
• W2166568517 creator A5038583094 @default.
• W2166568517 creator A5041242155 @default.
• W2166568517 creator A5050851341 @default.
• W2166568517 creator A5057378855 @default.
• W2166568517 creator A5057522959 @default.
• W2166568517 creator A5061915675 @default.
• W2166568517 creator A5071428717 @default.
• W2166568517 creator A5076930756 @default.
• W2166568517 creator A5079821454 @default.
• W2166568517 creator A5086523808 @default.
• W2166568517 date "2002-05-01" @default.
• W2166568517 modified "2023-09-27" @default.
• W2166568517 title "A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo." @default.
• W2166568517 cites W1443070471 @default.
• W2166568517 cites W1517260951 @default.
• W2166568517 cites W1550628230 @default.
• W2166568517 cites W1558366281 @default.
• W2166568517 cites W1970233009 @default.
• W2166568517 cites W1973702706 @default.
• W2166568517 cites W1978409389 @default.
• W2166568517 cites W1987269139 @default.
• W2166568517 cites W2012348490 @default.
• W2166568517 cites W2019490921 @default.
• W2166568517 cites W2031383072 @default.
• W2166568517 cites W2033268766 @default.
• W2166568517 cites W2041278387 @default.
• W2166568517 cites W2091759497 @default.
• W2166568517 cites W2128741716 @default.
• W2166568517 cites W2156888238 @default.
• W2166568517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12479263" @default.
• W2166568517 hasPublicationYear "2002" @default.
• W2166568517 type Work @default.
• W2166568517 sameAs 2166568517 @default.
• W2166568517 citedByCount "11" @default.
• W2166568517 countsByYear W21665685172012 @default.
• W2166568517 countsByYear W21665685172014 @default.
• W2166568517 countsByYear W21665685172015 @default.
• W2166568517 countsByYear W21665685172016 @default.
• W2166568517 countsByYear W21665685172019 @default.
• W2166568517 countsByYear W21665685172021 @default.
• W2166568517 crossrefType "journal-article" @default.
• W2166568517 hasAuthorship W2166568517A5005761697 @default.
• W2166568517 hasAuthorship W2166568517A5009676744 @default.
• W2166568517 hasAuthorship W2166568517A5013184259 @default.
• W2166568517 hasAuthorship W2166568517A5017385481 @default.
• W2166568517 hasAuthorship W2166568517A5017507332 @default.
• W2166568517 hasAuthorship W2166568517A5019353427 @default.
• W2166568517 hasAuthorship W2166568517A5020195400 @default.
• W2166568517 hasAuthorship W2166568517A5025950734 @default.
• W2166568517 hasAuthorship W2166568517A5030751523 @default.
• W2166568517 hasAuthorship W2166568517A5036690318 @default.
• W2166568517 hasAuthorship W2166568517A5038583094 @default.
• W2166568517 hasAuthorship W2166568517A5041242155 @default.
• W2166568517 hasAuthorship W2166568517A5050851341 @default.
• W2166568517 hasAuthorship W2166568517A5057378855 @default.
• W2166568517 hasAuthorship W2166568517A5057522959 @default.
• W2166568517 hasAuthorship W2166568517A5061915675 @default.
• W2166568517 hasAuthorship W2166568517A5071428717 @default.
• W2166568517 hasAuthorship W2166568517A5076930756 @default.
• W2166568517 hasAuthorship W2166568517A5079821454 @default.
• W2166568517 hasAuthorship W2166568517A5086523808 @default.
• W2166568517 hasConcept C121608353 @default.
• W2166568517 hasConcept C126322002 @default.
• W2166568517 hasConcept C134306372 @default.
• W2166568517 hasConcept C150903083 @default.
• W2166568517 hasConcept C197336794 @default.
• W2166568517 hasConcept C207001950 @default.
• W2166568517 hasConcept C2776694085 @default.
• W2166568517 hasConcept C2777132456 @default.
• W2166568517 hasConcept C2779723316 @default.
• W2166568517 hasConcept C2780192828 @default.
• W2166568517 hasConcept C33923547 @default.
• W2166568517 hasConcept C71924100 @default.
• W2166568517 hasConcept C86803240 @default.
• W2166568517 hasConcept C98274493 @default.
• W2166568517 hasConceptScore W2166568517C121608353 @default.
• W2166568517 hasConceptScore W2166568517C126322002 @default.
• W2166568517 hasConceptScore W2166568517C134306372 @default.
• W2166568517 hasConceptScore W2166568517C150903083 @default.
• W2166568517 hasConceptScore W2166568517C197336794 @default.
• W2166568517 hasConceptScore W2166568517C207001950 @default.
• W2166568517 hasConceptScore W2166568517C2776694085 @default.
• W2166568517 hasConceptScore W2166568517C2777132456 @default.
• W2166568517 hasConceptScore W2166568517C2779723316 @default.
• W2166568517 hasConceptScore W2166568517C2780192828 @default.
• W2166568517 hasConceptScore W2166568517C33923547 @default.

• next